Skip to main content
Hybio Pharmaceutical Co., Ltd. logo

Hybio Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300199 ISIN · CNE1000011T7 LEI · 300300SLUTRU2A8BDP64 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,483 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300199

About Hybio Pharmaceutical Co., Ltd.

https://www.hybio.com.cn

Hybio Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of peptide-based medicines. The company operates a vertically integrated platform covering the entire peptide value chain, from raw materials and active pharmaceutical ingredients (APIs) to finished dosage forms. Its product portfolio primarily targets metabolic disorders, cardiovascular diseases, and digestive health. Key offerings include GLP-1 receptor agonists such as Liraglutide and Semaglutide, alongside treatments like Teriparatide and Atosiban. Hybio maintains advanced production facilities compliant with international quality standards, enabling the supply of high-purity peptide products to global markets. The firm focuses on technological innovation in peptide synthesis and long-acting drug delivery systems to address unmet medical needs in chronic disease management.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is an announcement of the 2025 annual shareholders’ meeting resolutions, detailing attendance, vote counts, and the formal passing of agenda items. It reports voting results and confirms resolutions, matching the definition of Declaration of Voting Results & Voting Rights Announcements.
2026-05-20 Chinese
国浩律师关于翰宇药业2025年年度股东会的法律意见书
Regulatory Filings Classification · 92% confidence The document is a legal opinion letter issued by Grandall Law Firm (Shenzhen) regarding the convening, procedures, attendance, voting, and validity of the Shenzhen Hanyu Pharmaceutical Co., Ltd 2025 Annual General Meeting. It is essentially a lawyer’s attestation of legal compliance rather than a presentation deck or the AGM notice itself. Under the “CERTIFICATION RULE,” any certification, attestation, or confirmation letter—regardless of its subject—is classified as a Regulatory Filing (RNS). This letter primarily serves as a lawyers’ certification of the AGM process, so it falls under RNS.
2026-05-20 Chinese
关于卡贝缩宫素注射液获得印度尼西亚药品上市许可批准的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by Shenzhen Hanyu Pharma regarding the approval of a pharmaceutical product by a foreign regulator. It does not contain financial statements, management discussion of results, or details of corporate governance changes. It is a general regulatory disclosure rather than an earnings release, interim report, or capital update. It falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-14 Chinese
第六届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 13th meeting of the 6th Board of Directors of Shenzhen Hanyu Pharmaceutical Co., Ltd. It details the convening of the meeting, attendance, and the approval of key agenda items such as the change of the 2025 audit firm and the proposal to convene a 2026 second extraordinary shareholders' meeting. The document is a board meeting resolution announcement, not a full management report or audit report itself. It does not contain financial statements or detailed financial analysis. It is not a shareholder voting result announcement but a board meeting decision announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board decisions, consistent with MANG filings.
2026-02-25 Chinese
关于召开2026年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2026 second extraordinary general meeting (临时股东会) of Shenzhen Hanyu Pharmaceutical Co., Ltd. It includes information about the meeting time, voting methods (onsite and online), registration procedures, agenda items, and proxy forms. It does not contain any financial statements or results but is an announcement to shareholders about the meeting and voting process. The document length is 4245 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication that this is a report itself, but rather a notification about the meeting. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is a notice of the meeting and voting procedures rather than the solicitation materials or the voting results, it is best classified as Proxy Solicitation & Information Statement (PSI).
2026-02-25 Chinese
关于变更公司2025年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Shenzhen Hanyu Pharmaceutical Co., Ltd. regarding the change of the company's audit firm for the fiscal year 2025. It details the new audit firm, its qualifications, the reasons for the change, and the approval process including board and shareholder meetings. The document does not contain the audit report itself or detailed financial statements but is an official announcement about the change of auditor. The document length is 3445 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, it fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is primarily an announcement about the change of audit firm and not the audit report or results, it is best classified as Audit Report / Information (AR).
2026-02-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.